ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS).

Trial Profile

ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2010

At a glance

  • Drugs Ezetimibe; Niacin
  • Indications Atherosclerosis; Coronary disorders
  • Focus Therapeutic Use
  • Acronyms ARBITER-6-HALTS
  • Most Recent Events

    • 08 Apr 2010 Updated results published in Journal of the American College of Cardiology.
    • 15 Nov 2009 Results were presented during a late-breaking clinical trial session at the 82nd Annual Scientific Sessions of the American Heart Association (AHA).
    • 23 Jun 2009 Lead trial centre and sponsor (Abbott Laboratories) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top